Clinical and experimental aspects of novel antidiabetic therapies. From the gut and the kidney towards the cardiovascular system: the last ten years of the antidiabetic drugs.
Thursday, October 26th / 14.00-16.00
A matter of safety?|
The EMPAREG-OUTCOME study and the dilemma of the cardiovascular protection|
The point of view of the cardiologist|
Pasquale Perrone Filardi
The point of view of the diabetologist|
What the research tells us: mechanistic hypotheses of empaglifozin protection|